<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38060431</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>49</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</ArticleTitle><Pagination><StartPage>1327</StartPage><EndPage>1330</EndPage><MedlinePgn>1327-1330</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7249a3</ELocationID><Abstract><AbstractText>Poliovirus can cause poliomyelitis and lifelong paralysis. Although wild poliovirus types 2 and 3 have been eradicated, wild poliovirus type 1 and vaccine-derived polioviruses are still circulating in multiple countries worldwide. In 2022, a case of paralytic polio caused by vaccine-derived poliovirus type 2 was identified in an unvaccinated young adult in New York. This case and subsequent detection of community transmission underscored the ongoing risk for importation of poliovirus into the United States and risk for poliomyelitis among unvaccinated persons. However, previous Advisory Committee on Immunization Practices (ACIP) recommendations for adult polio vaccination were limited to adults known to be at increased risk for exposure. During October 2022-June 2023, the ACIP Polio Vaccine Work Group reviewed data on poliovirus surveillance and epidemiology, safety and effectiveness of inactivated poliovirus vaccine (IPV), and other considerations outlined in the ACIP Evidence to Recommendations Framework. On June 21, 2023, ACIP voted to recommend that all U.S. adults aged ≥18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio complete a primary polio vaccination series with IPV. This report summarizes evidence considered for this recommendation and provides clinical guidance for the use of IPV in adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kidd</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Routh</LastName><ForeName>Janell</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cineas</LastName><ForeName>Sybil</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bahta</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026683" MajorTopicYN="N">Advisory Committees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>13</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38060431</ArticleId><ArticleId IdType="pmc">PMC10715822</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7249a3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hall E, Wodi AP, Hamborsky J, et al., eds. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, DC: CDC, Public Health Foundation; 2021.</Citation></Reference><Reference><Citation>Prevots DR, Burr RK, Sutter RW, Murphy TV; Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(No. RR-5):1–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580728</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al.; 2022 U.S. Poliovirus Response Team. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater—New York, June–August 2022. MMWR Morb Mortal Wkly Rep 2022;71:1065–8. 10.15585/mmwr.mm7133e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7133e2</ArticleId><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryerson AB, Lang D, Alazawi MA, et al.; 2022 U.S. Poliovirus Response Team. Wastewater testing and detection of poliovirus type 2 genetically linked to virus isolated from a paralytic polio case—New York, March 9–October 11, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1418–24. 10.15585/mmwr.mm7144e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144e2</ArticleId><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference><Reference><Citation>New York State Department of Health. Poliovirus wastewater surveillance report. Albany, NY: New York State Department of Health; 2023. Accessed July 27, 2023. https://www.health.ny.gov/diseases/communicable/polio/docs/waste_water_surveillance_report.pdf</Citation></Reference><Reference><Citation>Hill HA, Chen M, Elam-Evans LD, Yankey D, Singleton JA. Vaccination coverage by age 24 months among children born during 2018–2019—National Immunization Survey–Child, United States, 2019–2021. MMWR Morb Mortal Wkly Rep 2023;72:33–8. 10.15585/mmwr.mm7202a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7202a3</ArticleId><ArticleId IdType="pmc">PMC9869730</ArticleId><ArticleId IdType="pubmed">36634013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995;754:289–99. 10.1111/j.1749-6632.1995.tb44462.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1995.tb44462.x</ArticleId><ArticleId IdType="pubmed">7625665</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997;16:312–22. 10.1097/00006454-199703000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199703000-00011</ArticleId><ArticleId IdType="pubmed">9076821</ArticleId></ArticleIdList></Reference><Reference><Citation>Estívariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013;3:309–15. 10.1016/j.coviro.2013.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2013.05.007</ArticleId><ArticleId IdType="pmc">PMC10395005</ArticleId><ArticleId IdType="pubmed">23759252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8:e1002599. 10.1371/journal.ppat.1002599</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002599</ArticleId><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok PW, Leeuwenburg J, Tukei P, et al. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ 1992;70:93–103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2393334</ArticleId><ArticleId IdType="pubmed">1568283</ArticleId></ArticleIdList></Reference><Reference><Citation>Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1–6. 10.1093/infdis/163.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/163.1.1</ArticleId><ArticleId IdType="pubmed">1845806</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. Polio vaccine inactivated. Package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-IPOL.pdf</Citation></Reference><Reference><Citation>Drucker J, Soula G, Diallo O, Fabre P. Evaluation of a new combined inactivated DPT-polio vaccine. Dev Biol Stand 1986;65:145–51.</Citation><ArticleIdList><ArticleId IdType="pubmed">3030861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001;107:e83. 10.1542/peds.107.5.e83</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.107.5.e83</ArticleId><ArticleId IdType="pubmed">11331733</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio vaccines [Chapter 7]. In: Stratton KR, Howe CJ, eds. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academy Press; 1994:187–210.</Citation><ArticleIdList><ArticleId IdType="pubmed">25144097</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal S, Shi J, Seib K, et al. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000–12. Lancet Infect Dis 2015;15:1175–82. 10.1016/S1473-3099(15)00059-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00059-6</ArticleId><ArticleId IdType="pubmed">26289956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace GS, Curns AT, Weldon WC, Oberste MS. Seroprevalence of poliovirus antibodies in the United States population, 2009–2010. BMC Public Health 2016;16:721. 10.1186/s12889-016-3386-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-016-3386-1</ArticleId><ArticleId IdType="pmc">PMC4974751</ArticleId><ArticleId IdType="pubmed">27492318</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick MP, Oberste MS, Moore D, Romero-Steiner S, Hansen CJ, Faix DJ. Effect of multiple, simultaneous vaccines on polio seroresponse and associated health outcomes. Vaccine 2015;33:2842–8. 10.1016/j.vaccine.2014.07.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.07.088</ArticleId><ArticleId IdType="pubmed">25131729</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominicus R, Galtier F, Richard P, Baudin M. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years. Vaccine 2014;32:3942–9. 10.1016/j.vaccine.2014.05.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.05.034</ArticleId><ArticleId IdType="pubmed">24852717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima S, Nakano T, Shimizu H, Hamada A. Immunogenicity of catch-up immunization with conventional inactivated polio vaccine among Japanese adults. Vaccines (Basel) 2022;10:2160. 10.3390/vaccines10122160</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122160</ArticleId><ArticleId IdType="pmc">PMC9785821</ArticleId><ArticleId IdType="pubmed">36560570</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimprel E, von Sonnenburg F, Sänger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005;23:3657–67. 10.1016/j.vaccine.2005.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.02.013</ArticleId><ArticleId IdType="pubmed">15882526</ArticleId></ArticleIdList></Reference><Reference><Citation>Larnaudie S, Guiso N, Baptiste C, et al. Humoral immunity of dTap-IPV vaccine (REPEVAX) administered one month after dT-IPV vaccine (REVAXIS) in adults with unknown vaccination history. Hum Vaccin 2010;6:829–34. 10.4161/hv.6.10.12582</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.6.10.12582</ArticleId><ArticleId IdType="pubmed">20864810</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial. Vaccine 2013;31:1496–502. 10.1016/j.vaccine.2012.12.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.12.081</ArticleId><ArticleId IdType="pubmed">23313654</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>